phentolamine mesylate - Profile

What are the generic drug sources for phentolamine mesylate and what is the scope of patent protection?

Phentolamine mesylate is the generic ingredient in four branded drugs marketed by Septodont Holding, Hikma, Precision Dose Inc, Novartis, and Famygen Life Sci, and is included in five NDAs. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Phentolamine mesylate has twenty-six patent family members in sixteen countries.

Summary for phentolamine mesylate

International Patents:	26
US Patents:	9
Tradenames:	4
Applicants:	5
NDAs:	5
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for phentolamine mesylate

Paragraph IV (Patent) Challenges for PHENTOLAMINE MESYLATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RYZUMVI	Ophthalmic Solution	phentolamine mesylate	0.75%	217064	1	2024-12-16

US Patents and Regulatory Information for phentolamine mesylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008		RX	Yes	Yes
Hikma	PHENTOLAMINE MESYLATE	phentolamine mesylate	INJECTABLE;INJECTION	040235-001	Mar 11, 1998	AP	RX	No	Yes
Precision Dose Inc	PHENTOLAMINE MESYLATE	phentolamine mesylate	INJECTABLE;INJECTION	207686-001	Jul 14, 2017	AP	RX	No	No
Novartis	REGITINE	phentolamine mesylate	INJECTABLE;INJECTION	008278-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for phentolamine mesylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008

International Patents for phentolamine mesylate

Country	Patent Number	Title	Estimated Expiration
Japan	2022505950	老眼、散瞳、および他の眼障害の治療のための方法および組成物
Japan	2016506966	フェントラミンの水性点眼液およびそれらの医学的用途
Australia	2018200566	AQUEOUS OPHTHALMIC SOLUTIONS OF PHENTOLAMINE AND MEDICAL USES THEREOF
Denmark	2950648

Phentolamine Mesylate: Investment Analysis of a Vasodilator for Erectile Dysfunction

Last updated: February 19, 2026

Phentolamine mesylate, a non-selective alpha-adrenergic antagonist, presents a complex investment landscape driven by its established, albeit niche, therapeutic applications, evolving patent expirations, and emerging competition in the erectile dysfunction (ED) market. While its direct-to-consumer market penetration has been limited, its use in specific medical scenarios and potential for combination therapies warrant detailed examination. This analysis evaluates the fundamental drivers for investment in phentolamine mesylate, focusing on market size, patent status, competitive pressures, and clinical utility.

What is the Current Market Size and Growth Trajectory for Phentolamine Mesylate?

The market for phentolamine mesylate is primarily segmented by its therapeutic indication. Historically, its most recognized application has been as a treatment for extravasation injury, a complication of certain intravenous drug administrations. In this context, the market size is directly tied to the prevalence of specific chemotherapy agents and other vasoactive drugs requiring this antidote [1].

A more significant, albeit less dominant, market segment is its use in treating erectile dysfunction (ED). Phentolamine mesylate, often formulated in combination with other agents like papaverine and phentolamine mesylate (often referred to as Trimix), is administered via intracavernosal injection. This delivery method positions it as a second- or third-line treatment option for ED refractory to oral pharmacotherapies such as phosphodiesterase type 5 (PDE5) inhibitors.

The global market for ED treatments was valued at approximately $6.9 billion in 2022 and is projected to reach $12.4 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.7% [2]. This overall market growth is influenced by an aging global population, increasing incidence of comorbidities like diabetes and cardiovascular disease that contribute to ED, and growing awareness and destigmatization of the condition.

Phentolamine mesylate's direct contribution to this market is relatively modest. Its market share within the ED space is constrained by:

• Delivery Method: Intracavernosal injections are invasive and less preferred by many patients compared to oral medications.
• Competition: Oral PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) dominate the first-line treatment of ED due to their ease of use and efficacy for a broad patient population.
• Niche Application: Its primary use remains in cases where oral treatments fail or are contraindicated.

However, specific market dynamics exist:

• Combination Therapies: Phentolamine mesylate is a key component of compounded injectable ED treatments, where market penetration is driven by urologists and specialized compounding pharmacies.
• Limited Geographic Penetration: While widely available in many developed markets, its accessibility and prescription patterns can vary significantly by region.

The growth trajectory for phentolamine mesylate specifically is likely to be slower than the overall ED market. It is expected to maintain its position as a niche treatment, with growth primarily linked to the increasing prevalence of severe ED cases and limited innovation in alternative injectable therapies. Projections for phentolamine mesylate's standalone market are not typically segmented in broad market reports, indicating its specialized nature. However, its use in compounded injectable solutions contributes to the overall growth of the specialized ED treatment market.

What are the Key Patent Expirations and Generic Competition Dynamics?

The patent landscape for phentolamine mesylate is characterized by the expiration of foundational patents, leading to a mature generic market for the active pharmaceutical ingredient (API) and its established formulations.

Original Patents and Expirations:

Phentolamine mesylate was first synthesized and patented in the mid-20th century. The original compound patents have long expired, allowing for generic manufacturing of the API. For instance, U.S. Patent No. 2,749,328, covering a method for preparing phentolamine, was filed in 1954 and expired decades ago [3]. Similarly, patents related to its early pharmaceutical compositions and therapeutic uses are also expired.

Generic Market Landscape:

The generic status of phentolamine mesylate means that multiple manufacturers produce and market the API. This has resulted in significant price competition for the raw material. Key implications of this generic market include:

• API Cost Reduction: The cost of procuring phentolamine mesylate API is relatively low, benefiting formulators, especially those producing compounded medications.
• Limited Brand Exclusivity: For standalone phentolamine mesylate products (e.g., for extravasation), there is minimal brand loyalty due to the availability of multiple generic equivalents.
• Focus on Formulation Innovation: Any patentable innovation related to phentolamine mesylate would likely focus on novel drug delivery systems, combination therapies, or specific indications rather than the molecule itself.

Current Patent Activity:

While the core molecule is off-patent, companies may hold patents on:

• Specific Formulations: New formulations designed for improved stability, efficacy, or patient compliance (e.g., pre-filled syringes, novel injectable solutions with extended shelf life).
• Combination Therapies: Patents for specific combinations of phentolamine mesylate with other active pharmaceutical ingredients (APIs) for synergistic effects in treating ED or other conditions.
• Manufacturing Processes: Patents for optimized or more efficient manufacturing processes for the API or finished dosage forms.
• New Indications: Patents for the use of phentolamine mesylate in previously unexplored therapeutic areas, though this is less likely given its established pharmacological profile.

A review of patent databases (e.g., USPTO, Espacenet) reveals ongoing patent filings related to drug delivery and combination therapies involving phentolamine, particularly within the ED treatment sector. For example, patents might cover specific ratios of phentolamine mesylate with papaverine and atropine (Trimix formulations) or novel methods of preparing these mixtures for enhanced stability and efficacy.

Impact on Investment:

The absence of strong, enduring patent protection for phentolamine mesylate itself limits opportunities for substantial revenue growth based on market exclusivity. Investment theses would need to focus on:

• Companies with proprietary formulations or delivery systems that offer a competitive advantage.
• Manufacturers of compounded injectable ED treatments that leverage phentolamine mesylate as a key ingredient and have established relationships with prescribing physicians.
• Companies developing novel combination therapies where phentolamine mesylate plays a synergistic role.

The generic nature of the API allows for lower manufacturing costs, which can be a competitive advantage for formulators. However, it also intensifies price pressure and necessitates differentiation through product quality, service, or unique market positioning.

What is the Competitive Landscape for Erectile Dysfunction Treatments?

The erectile dysfunction (ED) treatment market is highly competitive, dominated by oral phosphodiesterase type 5 (PDE5) inhibitors. Phentolamine mesylate, primarily in its injectable form and combination therapies, occupies a specific, secondary tier of treatment.

Primary Competition: Oral PDE5 Inhibitors

• Sildenafil (Viagra, Revatio): The first-in-class PDE5 inhibitor, widely prescribed and recognized. Generic sildenafil is widely available and inexpensive.
• Tadalafil (Cialis, Adcirca): Known for its longer duration of action. Generic tadalafil is also available.
• Vardenafil (Levitra, Staxyn): Another option with a generally favorable efficacy profile. Generic vardenafil is available.
• Avanafil (Stendra): A newer PDE5 inhibitor claiming faster onset of action and potentially fewer side effects for some users.

These oral medications are the first-line treatment for most men with ED due to their efficacy, ease of use, and non-invasive nature.

Secondary Competition: Injectable Therapies

Phentolamine mesylate is a key component of injectable ED treatments, typically combined with papaverine and/or atropine. These are often referred to by various proprietary or compounded names (e.g., Trimix, Bimix).

• Mechanism: These injections are administered directly into the corpus cavernosum, inducing penile erection through smooth muscle relaxation and increased blood flow.
• Patient Profile: These are generally reserved for patients who do not respond adequately to oral PDE5 inhibitors or have contraindications to their use (e.g., severe cardiovascular issues, certain medications like nitrates).
• Competitive Advantages of Injectables:
  • Higher success rates for severe ED.
  • Can be effective in patients with vascular, neurological, or psychological causes of ED.
• Competitive Disadvantages of Injectables:
  • Invasive administration requiring patient training and manual dexterity.
  • Risk of pain, bruising, and priapism (prolonged erection).
  • Requires compounding, leading to variability in formulation and potential for higher cost compared to generic oral medications.
  • Social and psychological barriers to self-injection.

Other Treatment Modalities:

• Vacuum Erection Devices (VEDs): Non-pharmacological option, useful for men who cannot or prefer not to use medications.
• Intraurethral Suppositories (e.g., Alprostadil): Another delivery method for ED treatment, less invasive than injection but with its own set of efficacy and side effect profiles.
• Testosterone Replacement Therapy (TRT): Used when hypogonadism is identified as a contributing factor to ED.
• Penile Implants: Surgical option for severe, refractory ED.

Phentolamine Mesylate's Competitive Position:

Phentolamine mesylate, as part of injectable formulations, competes effectively within its niche. Its primary advantage is its established efficacy in achieving erections when other treatments fail. However, its growth potential is capped by the inherent limitations of injectable administration and the widespread availability and patient preference for oral therapies.

Investment in this space for phentolamine mesylate would likely target companies that:

• Specialize in compounding high-quality, stable injectable ED treatments.
• Develop innovative delivery devices or formulations that improve patient experience or product efficacy for injectables.
• Are involved in research for novel combination therapies that might include phentolamine mesylate for specific ED subtypes.

The market for phentolamine mesylate in ED is not about capturing market share from oral PDE5 inhibitors but about serving a segment of the ED population for whom these inhibitors are insufficient.

What are the Clinical Utility and Future Development Potential for Phentolamine Mesylate?

Phentolamine mesylate's established pharmacological profile provides a clear clinical utility, but its future development potential is nuanced and largely dependent on innovation in delivery and combination therapies rather than novel indications.

Established Clinical Utility:

1. Treatment of Extravasation Injury: Phentolamine mesylate is a recognized antidote for extravasation of alpha-adrenergic stimulating agents, particularly norepinephrine and dopamine. Its ability to antagonize alpha-receptors causes vasodilation, counteracting the vasoconstrictive effects of these drugs and preventing tissue necrosis. This remains a critical, albeit low-volume, application in hospital settings.
2. Treatment of Erectile Dysfunction (ED): As discussed, it is a key component of intracavernosal injections for ED. It functions by blocking alpha-adrenergic receptors in the smooth muscle of the corpus cavernosum, promoting relaxation and facilitating blood inflow necessary for erection. It is particularly effective for ED related to vascular insufficiency.
3. Management of Phentolamine-Induced Hypertension: In rare instances, it can be used to manage severe hypertension caused by the use of certain sympathomimetic drugs or pheochromocytoma [4].

Future Development Potential:

The primary avenue for future development of phentolamine mesylate lies in optimizing its existing applications, rather than discovering entirely new uses.

• Enhanced Injectable Formulations for ED:
  • Improved Stability and Shelf-Life: Compounded injectables can have limited stability. Development of formulations with extended shelf-life and consistent potency would be beneficial.
  • Reduced Pain and Discomfort: Research into co-formulations or additives that minimize injection site pain or bruising could improve patient compliance.
  • Novel Delivery Systems: Exploration of micro-needle patches or other transdermal or less invasive delivery methods, though challenging for achieving direct penile pharmacokinetics, could be a long-term research goal.
• Combination Therapies:
  • Synergistic ED Treatments: Investigating novel combinations with other vasodilators, growth factors, or agents targeting different pathways of erectile function could lead to improved efficacy or address specific etiologies of ED.
  • Other Vasospastic Conditions: While speculative, its vasodilatory properties might be explored in other conditions characterized by vasospasm, provided safety and efficacy can be demonstrated and differentiated from existing treatments.
• Targeted Drug Delivery: Research into micro-encapsulation or nanoparticle delivery systems could potentially improve the localized action and reduce systemic side effects of phentolamine mesylate, though the cost-effectiveness for its current indications would be a significant hurdle.
• Repurposing for Rare Indications: While its primary uses are well-defined, ongoing screening of existing drugs for novel therapeutic applications is a continuous process in pharmaceutical research. However, the low volume of its current use and its mechanism of action make it less likely to be a prime candidate for broad repurposing compared to drugs with more versatile targets.

Challenges to Development:

• Generic Status: The lack of patent protection on the molecule itself significantly reduces the financial incentive for large-scale R&D investment in novel indications or basic research. Investment is more likely to come from companies focused on specialized formulations or compounding.
• Market Size for Niche Applications: The market for extravasation treatment is small. For ED, while the overall market is large, phentolamine's role is confined to a segment that is already well-served by other modalities.
• Competition from Established Therapies: The dominance of oral PDE5 inhibitors in ED presents a high barrier for any new treatment modality to gain significant traction.

The future development of phentolamine mesylate appears to be concentrated on incremental improvements in its established applications, particularly for injectable ED treatments, and potentially in the development of carefully designed combination therapies.

What are the Regulatory Considerations and Safety Profile?

Phentolamine mesylate, as an established pharmaceutical agent, is subject to standard regulatory oversight for its approved indications. Its safety profile is well-characterized, but specific considerations apply to its use.

Regulatory Status:

• Approved Indications: Phentolamine mesylate is approved by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for specific uses.
  • Extravasation: Approved as an antidote for extravasation of peripheral vasoconstrictive drugs.
  • Diagnostic Use (Historical): Previously used as a diagnostic agent for pheochromocytoma, although this use has largely been superseded by more specific imaging and laboratory tests.
• Compounded Medications: When used in compounded injectable formulations for ED, the regulatory framework becomes more complex. Compounding pharmacies operate under specific regulations (e.g., USP <795> and <800> in the US) that address compounding quality, safety, and record-keeping. These regulations differ from those for commercially approved, mass-produced drugs.
• Off-Label Use: Use in ED, while common, can be considered off-label if a specific compounded formulation is not approved by a regulatory authority for that indication. Prescribing physicians bear the responsibility for the decision to use medications off-label based on their professional judgment and the patient's best interest.

Safety Profile and Side Effects:

Phentolamine mesylate is generally considered safe when used appropriately, but it has a range of potential side effects, particularly related to its vasodilatory and adrenergic blocking actions.

Common Side Effects (particularly with injection):

• Cardiovascular: Hypotension (low blood pressure), tachycardia (rapid heart rate), dizziness, flushing.
• Local Injection Site Reactions: Pain, swelling, bruising, bleeding.
• Gastrointestinal: Nausea, vomiting, diarrhea.
• Neurological: Headache, weakness, numbness.

Serious Side Effects:

• Priapism: A prolonged erection lasting more than four hours, requiring immediate medical attention to prevent permanent damage. This is a significant risk with intracavernosal injections.
• Severe Hypotension: Can lead to syncope or collapse.
• Myocardial Infarction (Heart Attack) and Stroke: Rare but possible, especially in individuals with underlying cardiovascular disease.
• Nasal Congestion and Rhinorrhea: Can occur with nasal spray formulations (historically used for other applications).

Contraindications:

• Known hypersensitivity to phentolamine mesylate.
• Conditions where vasodilation could be dangerous (e.g., severe coronary artery disease, a history of myocardial infarction, active peptic ulcer disease in some contexts).
• Patients taking monoamine oxidase inhibitors (MAOIs) or other sympathomimetic agents without careful consideration.

Drug Interactions:

• Sympathomimetic Amines: Phentolamine can potentiate the pressor effects of epinephrine and other sympathomimetic amines, paradoxically causing reflex bradycardia and further vasodilation.
• Antihypertensives: May enhance the hypotensive effects of other blood pressure-lowering medications.

Regulatory Considerations for Investment:

• FDA Approvals: Companies seeking to market new, approved formulations or indications for phentolamine mesylate would need to navigate the standard FDA drug approval process (e.g., New Drug Application - NDA), requiring extensive clinical trials.
• Compounding Pharmacy Landscape: Investment in companies supporting the compounded medication market for phentolamine mesylate involves understanding the evolving regulatory environment for compounding pharmacies, which has seen increased scrutiny and enforcement regarding the distinction between compounding and manufacturing.
• Post-Market Surveillance: As with all pharmaceuticals, ongoing pharmacovigilance and adverse event reporting are crucial for monitoring the safety of phentolamine mesylate in real-world use.

The well-established safety profile, albeit with a clear risk of priapism for ED injections, allows for its continued use. However, any investment focused on product development must consider the rigorous regulatory pathways and the specific challenges associated with compounded therapies.

Key Takeaways

Phentolamine mesylate occupies a niche but clinically relevant position in the pharmaceutical market. Its investment profile is shaped by a mature generic API market, limited patent exclusivity, and competition primarily within specific therapeutic domains.

• Market Position: Dominant as a second- or third-line injectable treatment for ED, and established as an antidote for extravasation injury. Its contribution to the overall ED market is modest but stable.
• Patent Status: The molecule is off-patent, leading to generic availability of the API. Innovation opportunities lie in proprietary formulations, delivery systems, and combination therapies.
• Competitive Landscape: Faces competition from oral PDE5 inhibitors in ED and other established antidotes or supportive care in extravasation. Its strength lies in its efficacy where other treatments fail.
• Clinical Utility: Proven in ED and extravasation. Future development potential is primarily in optimizing existing applications and exploring synergistic combinations.
• Regulatory and Safety: Well-understood safety profile with recognized risks (e.g., priapism). Regulatory pathways are clear for established uses, but compounding regulations add complexity.

Investment in phentolamine mesylate is best suited for strategies focused on specialized pharmaceutical services, compounding, or innovative formulation development rather than on novel molecule discovery.

Frequently Asked Questions

1. What are the primary indications for phentolamine mesylate that drive current market demand? Phentolamine mesylate's primary market demand is driven by its use in treating erectile dysfunction (ED) via intracavernosal injection and as an antidote for extravasation injury of specific vasoactive drugs.

2. Given that phentolamine mesylate is an older drug, are there any opportunities for new patents or intellectual property protection? While the core molecule is off-patent, opportunities for new intellectual property exist in novel drug formulations, improved delivery systems (e.g., enhanced stability for injectables), synergistic combination therapies for ED, and potentially optimized manufacturing processes.

3. How does phentolamine mesylate's efficacy compare to oral ED treatments like sildenafil or tadalafil? Phentolamine mesylate is typically reserved for ED patients who do not respond adequately to oral PDE5 inhibitors or have contraindications to their use. It is administered via injection and is generally considered more potent for achieving erection in severe cases but is less convenient and carries higher risks of local side effects and priapism.

4. What are the major risks associated with investing in companies that produce or formulate phentolamine mesylate? Key risks include intense price competition due to generic API availability, limited growth potential for established indications, the complex regulatory environment for compounded medications, and the inherent safety risks associated with injectable therapies, particularly priapism in ED treatment.

5. Are there any emerging therapeutic areas where phentolamine mesylate's pharmacological properties might be explored for future development? While its primary uses are well-defined, its vasodilatory and alpha-adrenergic antagonist properties could theoretically be explored for other rare vasospastic conditions. However, significant investment in exploring entirely new indications is unlikely given the molecule's generic status and the cost-benefit analysis compared to developing novel agents.

Citations

[1] National Center for Biotechnology Information. (2023). Phentolamine Mesylate. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK548727/

[2] Grand View Research. (2023). Erectile Dysfunction Drugs Market Size, Share & Trends Analysis Report By Drug Class (PDE5 Inhibitors, Testosterone, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And Segment Forecasts, 2023 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/erectile-dysfunction-drugs-market

[3] United States Patent and Trademark Office. (1954). U.S. Patent 2,749,328 A: Process of preparing phentolamine. Retrieved from https://patents.google.com/patent/US2749328A/

[4] U.S. Food & Drug Administration. (n.d.). Phentolamine Mesylate Injection Label. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050072s023lbl.pdf